New advocates act most effectively in the destruction of cancer cells
Posted on November 21, 2018, 11h35 – 21 November 2018, 11:30 am
Scientists at Southampton University in England have developed a new antibody that can be the key to resolving the defense process. cancer immune system. The new ally would have the ability to move twice to encourage the destruction of cancer cells.
Study published in scientific journal Cell, The team working in the Cancer Immunology Center at the University of Southampton, United Kingdom, says they have developed specific antibodies to label an immune receptor, called 4-1BB, that can activate cytotoxic T lymphocytes (known as "killers") because they and killing the cancer cells.
According to the scientific dissemination website News-MedicalThe team discovered that 4-1BB was found in a group of lymphocytes within the tumor called "regulators" which deactivate cytotoxic lymphocytes. The solution examined by scientists is the exclusion of regulatory cells, so that it is possible to activate "killers".
The new antibody has two purposes
In previous studies, it was observed that 4-1BB play may cause a decrease in tumor size. However, the same antibody that cleanses the regulatory cells was not the same as activating the cytotoxic ones, which prevented a sufficient therapeutic approach scenario.
The novelty of the English study is that the developed antibody may be dual-functional according to the laboratory results. The team has been investigating the subject for more than a decade and believes the discovery can lead to a new wave of cancer antibodies.
Lar Immunotherapy with antibodies changed the results of patients with various cancers, but responses are usually limited to a minority, sınırlı said Professor Stephen Beers, who led the study. . This is really exciting. The immune antibodies that activate receptors like 4-1BB were unable to convert the results into the clinical picture, but they have a great potential if we can understand how we can successfully target them in cancer patients, "he said.
For the time being, the observed results can be applied to ovarian cancer and a specific type of skin cancer, but the team hopes to replicate work to other species in the near future.